DelMar Pharmaceuticals Company Profile (OTCMKTS:DMPI)

About DelMar Pharmaceuticals

DelMar Pharmaceuticals logoDelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. Its drug candidate, VAL-083, is used in the United States as a treatment for glioblastoma multiforme (GBM). In addition to its clinical development activities in the United States, the Company has obtained certain exclusive commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its VAL-083 is granted orphan drug status by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The Company's product,VAL-083, represents a small molecule chemotherapeutic, which means that the molecular structure of VAL-083 is not an analogue or derivative of other small molecule chemotherapeutics approved for the treatment of cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: OTCMKTS
  • Symbol: DMPI
  • CUSIP:
Key Metrics:
  • Previous Close: $6.30
  • 50 Day Moving Average: $7.61
  • 200 Day Moving Average: $4.11
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.08
  • P/E Growth: 0.00
  • Market Cap: $63.40M
  • Outstanding Shares: 10,063,000
  • Beta: 0.94
Additional Links:
Companies Related to DelMar Pharmaceuticals:

Analyst Ratings

Consensus Ratings for DelMar Pharmaceuticals (OTCMKTS:DMPI) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.00

Analysts' Ratings History for DelMar Pharmaceuticals (OTCMKTS:DMPI)
Show:
DateFirmActionRatingPrice TargetDetails
7/18/2016Rodman & RenshawReiterated RatingBuyView Rating Details
2/18/2016Roth CapitalInitiated CoverageBuyView Rating Details
(Data available from 8/24/2014 forward)

Earnings

Earnings History for DelMar Pharmaceuticals (OTCMKTS:DMPI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/2/2016        
5/13/2016($0.05)($0.03)ViewN/AView Earnings Details
5/18/2015($0.07)($0.04)ViewN/AView Earnings Details
2/12/2015($0.06)($0.03)ViewN/AView Earnings Details
11/11/2014($0.07)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for DelMar Pharmaceuticals (OTCMKTS:DMPI)
Current Year EPS Consensus Estimate: $-0.69 EPS
Next Year EPS Consensus Estimate: $-0.78 EPS

Dividends

Dividend History for DelMar Pharmaceuticals (OTCMKTS:DMPI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for DelMar Pharmaceuticals (OTCMKTS:DMPI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/25/2015Jeffrey BachaCEOBuy7,500$1.47$11,025.00View SEC Filing  
10/8/2015Jeffrey BachaCEOBuy3,000$0.80$2,400.00View SEC Filing  
9/18/2015Jeffrey BachaCEOBuy4,000$0.83$3,320.00View SEC Filing  
7/22/2015Dennis M BrownMajor ShareholderBuy75,000$0.60$45,000.00View SEC Filing  
7/16/2015Jeffrey BachaCEOBuy50,000$0.60$30,000.00View SEC Filing  
7/16/2015William J GarnerDirectorBuy16,666$0.60$9,999.60View SEC Filing  
1/22/2015Jeffrey BachaCEOBuy7,500$0.66$4,950.00View SEC Filing  
12/9/2014Jeffrey BachaCEOBuy2,500$0.90$2,250.00View SEC Filing  
11/26/2014Jeffrey BachaCEOBuy2,500$0.92$2,300.00View SEC Filing  
11/21/2014John K BellDirectorBuy8,000$0.95$7,600.00View SEC Filing  
9/18/2014Jeffrey BachaCEOBuy4,000$0.98$3,920.00View SEC Filing  
9/15/2014Jeffrey BachaCEOBuy4,985$0.75$3,738.75View SEC Filing  
9/8/2014John K BellDirectorBuy7,000$0.71$4,970.00View SEC Filing  
9/4/2014John K BellDirectorBuy8,000$0.78$6,240.00View SEC Filing  
4/22/2014John K BellDirectorBuy20,000$1.25$25,000.00View SEC Filing  
3/18/2014Dennis M BrownMajor ShareholderBuy10,000$1.30$13,000.00View SEC Filing  
3/18/2014Robert Joseph Toth JrDirectorBuy25,000$1.30$32,500.00View SEC Filing  
3/4/2014Dennis M BrownMajor ShareholderBuy5,000$1.56$7,800.00View SEC Filing  
2/21/2014Jeffrey BachaCEOBuy5,000$1.00$5,000.00View SEC Filing  
2/13/2014Jeffrey BachaCEOBuy5,000$0.80$4,000.00View SEC Filing  
2/11/2014John K BellDirectorBuy9,000$0.83$7,470.00View SEC Filing  
2/5/2014Robert Joseph Toth JrDirectorBuy9,000$0.88$7,920.00View SEC Filing  
1/31/2014Robert Joseph Toth JrDirectorBuy2,000$0.87$1,740.00View SEC Filing  
1/29/2014Robert Joseph Toth JrDirectorBuy7,500$0.91$6,825.00View SEC Filing  
9/20/2013William J GarnerDirectorBuy5,000$1.00$5,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for DelMar Pharmaceuticals (OTCMKTS:DMPI)
DateHeadline
finance.yahoo.com logoDMPI: We Set our new Valuation at $16.00 per share Post Reverse Split and Uplisting on NASDAQ (OTCMKTS:DMPI)
finance.yahoo.com - August 3 at 4:45 PM
thestreet.com logoDelMar Pharmaceuticals Shares Decline on Thursday After Being Uplisted to Nasdaq (OTCMKTS:DMPI)
www.thestreet.com - July 14 at 6:09 PM
4-traders.com logoNasdaq : Launches Powerful New Tool for Communications and Marketing Professionals to Seamlessly Leverage Industry Influencers (OTCMKTS:DMPI)
www.4-traders.com - July 14 at 4:54 PM
publicnow.com logoDelMar Pharmaceuticals Inc. (Nasdaq: DMPI) to Ring The Nasdaq Stock Market Opening Bell (OTCMKTS:DMPI)
www.publicnow.com - July 13 at 10:18 AM
bizjournals.com logoDelMar Pharmaceuticals Announces Approval for Listing on NASDAQ (OTCMKTS:DMPI)
www.bizjournals.com - July 11 at 9:26 AM

Social

DelMar Pharmaceuticals (OTCMKTS:DMPI) Chart for Wednesday, August, 24, 2016


Last Updated on 8/24/2016 by MarketBeat.com Staff